CN1946403A - 氟班色林在治疗经前期及其他女性的性功能障碍中的用途 - Google Patents
氟班色林在治疗经前期及其他女性的性功能障碍中的用途 Download PDFInfo
- Publication number
- CN1946403A CN1946403A CNA2005800126174A CN200580012617A CN1946403A CN 1946403 A CN1946403 A CN 1946403A CN A2005800126174 A CNA2005800126174 A CN A2005800126174A CN 200580012617 A CN200580012617 A CN 200580012617A CN 1946403 A CN1946403 A CN 1946403A
- Authority
- CN
- China
- Prior art keywords
- flibanserin
- acid
- pharmaceutically
- sexual
- described method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229960002053 flibanserin Drugs 0.000 title claims abstract description 40
- 208000012201 sexual and gender identity disease Diseases 0.000 title abstract 2
- 208000015891 sexual disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 33
- 239000002253 acid Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000001568 sexual effect Effects 0.000 claims description 8
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 7
- 208000027520 Somatoform disease Diseases 0.000 claims description 7
- 208000027753 pain disease Diseases 0.000 claims description 7
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims description 5
- 208000021663 Female sexual arousal disease Diseases 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 208000029899 Sexual aversion disease Diseases 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 208000004483 Dyspareunia Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 208000014840 female orgasmic disease Diseases 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 2
- 201000004197 inhibited female orgasm Diseases 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 44
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 32
- 235000019359 magnesium stearate Nutrition 0.000 description 16
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 14
- 238000009501 film coating Methods 0.000 description 13
- 239000007888 film coating Substances 0.000 description 13
- 229920002261 Corn starch Polymers 0.000 description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
- 239000013543 active substance Substances 0.000 description 10
- 239000008120 corn starch Substances 0.000 description 10
- 239000000454 talc Substances 0.000 description 10
- 235000012222 talc Nutrition 0.000 description 10
- 229910052623 talc Inorganic materials 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 229920003091 Methocel™ Polymers 0.000 description 9
- 229960001375 lactose Drugs 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 235000010215 titanium dioxide Nutrition 0.000 description 7
- 239000004408 titanium dioxide Substances 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229960001021 lactose monohydrate Drugs 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- -1 aliphatic alcohols Chemical class 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及治疗经前期及其他女性的性功能障碍的方法，所述方法包括给药治疗有效量的氟班色林(flibanserin)。
Description
本发明涉及治疗经前期及其他女性的性功能障碍的方法，所述方法包括给药治疗有效量的氟班色林。
发明描述
化合物1-[2-(4-(3-三氟甲基-苯基)哌嗪-1-基)乙基]-2，3-二氢-1H-苯并咪唑-2-酮(氟班色林)(flibanserin)是以其盐酸盐的形式公开于欧洲专利申请案EP-A-526434中，并具有下列的化学结构。
氟班色林显示出对5-HT1A及5-HT2-受体具有亲和力。因此它是一种治疗多种疾病例如抑郁症、精神分裂症和焦虑症的有前途的治疗剂。
在对患有性功能障碍的女性患者的研究中已发现，任选为其药学上可接受的酸加成盐形式的氟班色林被证明对治疗性功能障碍有效。因此，本发明涉及一种治疗经前期疾病(premenstrual disorders)的方法，其包括给药治疗有效量的氟班色林，氟班色林任选为其药学上可接受的酸加成盐的形式。
在一个优选的实施方案中，本发明涉及治疗经前期疾病的方法，所述经前期疾病选自：经前期焦虑、经前期综合征、经前期焦虑症，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
在另一个优选的实施方案中，本发明涉及治疗女性性厌恶障碍(sexualaversion disorder)的方法，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
在另一个优选的实施方案中，本发明涉及治疗女性性唤醒障碍(sexualarousal disorder)的方法，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
在另一个优选的实施方案中，本发明涉及治疗女性性高潮障碍(orgasmic disorder)的方法，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
在另一个优选的实施方案中，本发明涉及治疗女性性交痛障碍(sexualpain disorder)的方法，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
在一个特别优选的实施方案中，本发明涉及治疗性交痛障碍的方法，所述性交痛障碍选自：交媾困难、阴道痉挛、非接触式性交痛障碍(noncoitalsexual pain disorder)、由一般疾病症状(medical condition)导致的性功能障碍及物质引起的性功能障碍，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
本发明的另一个实施方案涉及任选为其药学上可接受的酸加成盐形式的氟班色林的用途，其用于制备治疗上述疾病的药物。
氟班色林的有益效果都可观察到，不管该疾病是否为终身的或是后天得到的，并且不依赖于病原学起因(器官上的(躯体上(physically)和药物引发的)、心理的、器官上的(躯体上和药物引发的)及心理上的组合，或未知的)。
氟班色林可任选以其药学上可接受的酸加成盐的形式使用。合适的酸加成盐包括例如选自琥珀酸、氢溴酸、醋酸、延胡索酸、马来酸、甲磺酸、乳酸、磷酸、盐酸、硫酸、酒石酸和柠檬酸的那些酸所形成的盐。也可使用上述酸加成盐的混合物。在上述所提及的酸加成盐中，优选盐酸盐和氢溴酸盐，特别优选盐酸盐。
氟班色林，任选以其药学上可接受的酸加成盐的形式使用，其可被混合到固体、液体和喷雾剂形式的常规的药物制剂中。该组合物可例如以适合口服、直肠、肠胃外给药或鼻内吸入的形式存在，优选的形式包括例如胶囊、片剂、包衣片剂、安瓿、栓剂及鼻腔喷雾(nasal spray)。
可将活性成分混合到常规用于药物组合物的赋形剂或载体中，例如滑石、阿拉伯胶、乳糖、明胶、硬脂酸镁、玉米淀粉、水性(acqueous)或非水性的媒介、聚乙烯吡咯酮、半合成的脂肪酸甘油酯、苯扎氯铵(benzalconiumchloride)、磷酸钠、EDTA、聚山梨醇酯80。有利地，可将该组合物配置成单元剂量，每一单元剂量适于提供单次剂量的活性成分。可适用的剂量范围为每天0.1至400mg之间，优选是1.0至300mg之间，更优选是2至200mg之间。每一单元剂量可方便地含有0.01至100mg，优选为0.1至50mg。
合适的片剂可通过，例如将活性物质与已知的赋形剂，例如惰性稀释剂如碳酸钙、磷酸钙或乳糖，崩解剂如玉米淀粉或海藻酸，粘合剂如淀粉或明胶，润滑剂如硬脂酸镁或滑石和/或延迟释放剂如羧甲基纤维素、苯二甲酸醋酸纤维素，或聚乙酸乙烯酯混合来制得。该片剂也可包含数层。
相应地，包衣片剂可通过将制得的类似片剂的片心涂覆上通常用于片剂包衣的物质，例如克利酮(collidone)或紫胶(shellac)、阿拉伯胶、滑石、二氧化钛或糖来制备。为了要达到缓释或防止不相容性，该片心也可包含许多层。同样地，片剂包衣可包含许多层来达到缓释，或者使用上述提及的用于片剂的赋形剂。
根据本发明含有活性物质的糖浆剂或酏剂或其组合可另外包含增甜剂，例如糖精、环己烷氨基磺酸盐(cyclamate)、甘油或糖和增味剂，例如调味剂如香草素(vanilline)或柑橘萃取物。它们也可包含混悬剂佐剂或增稠剂如羧甲基纤维素钠，湿润剂例如脂肪醇类与环氧乙烷的缩合产物，或防腐剂如对羟基苯甲酸酯(benzoate)。
注射用的溶液是根据一般方法制备的，例如加入防腐剂如对羟基苯甲酸酯或稳定剂如乙二胺四乙酸的碱金属盐，并转移至注射小瓶或安瓿中。
包含一种或多种活性物质或活性物质组合的胶囊例如可通过下面方法制备得到：将活性物质与惰性载体如乳糖或山梨糖醇混合，并将它们装入明胶胶囊中。
合适的栓剂例如可通过与为此目的而提供的载体如中性脂肪或聚乙二醇或其衍生物混合来制备。
以下实施例是说明本发明而非限制其范围：
药物制剂的实例
A)片剂 每一片剂
氟班色林盐酸盐 100mg
乳糖 240mg
玉米淀粉 340mg
聚乙烯吡咯酮 45mg
硬脂酸镁 15mg
740mg
将磨成细粉状的活性物质、乳糖和一些玉米淀粉一起混合。将混合物过筛，然后用聚乙烯吡咯酮的水溶液湿润、捏和、湿法制粒并干燥。将该颗粒、剩下的玉米淀粉和硬脂酸镁过筛并混合在一起。将混合物压制成合适形状及大小的片剂。
B)片剂 每一片剂
氟班色林盐酸盐 80mg
玉米淀粉 190mg
乳糖 55mg
微晶纤维素 35mg
聚乙烯吡咯酮 15mg
羧甲基淀粉钠 23mg
硬脂酸镁 2mg
400mg
将磨成细粉状的活性物质、一些玉米淀粉、乳糖、微晶纤维素和聚乙烯吡咯酮一起混合，将混合物过筛，并用剩余的玉米淀粉和水处理形成颗粒，将其干燥并过筛。加入羧甲基淀粉钠和硬脂酸镁并混合，将混合物压制以形成合适大小的片剂。
C)包衣片剂 每一包衣片剂
氟班色林盐酸盐 5mg
玉米淀粉 41.5mg
乳糖 30mg
聚乙烯吡咯酮 3mg
硬脂酸镁 0.5mg
80mg
将活性物质、玉米淀粉、乳糖和聚乙烯吡咯酮充分混合，并用水湿润。将润湿的团块状物通过1mm筛目大小的筛网，于约45℃干燥，并然后将颗粒通过相同的筛网。在将硬脂酸镁混入后，在造粒机(tablet-making machine)中压成直径6mm的凸面片剂片心。将由此制备的片剂片心通过已知的方法涂覆基本上由糖和滑石组成的包衣。将制成的包衣片剂用蜡抛光。
D)胶囊 每一胶囊
氟班色林盐酸盐 150mg
玉米淀粉 268.5mg
硬脂酸镁 1.5mg
4200mg
将物质和玉米淀粉混合并以水湿润。将润湿的团块状物过筛并干燥。将干燥的颗粒过筛并与硬脂酸镁混合。将制成的混合物装入1号大小的硬明胶胶囊中。
E)安瓿溶液
氟班色林盐酸盐 50mg
氯化钠 50mg
注射用水 5ml
在其本身的pH或任选在pH为5.5-6.5下，将活性物质溶于水中，并加入氯化钠使其等张。在无热原下将得到的溶液过滤，将该滤液在无菌条件下转移到安瓿中，然后将其灭菌并熔封。
F)栓剂
氟班色林盐酸盐 50mg
固体脂肪 1650mg
1700mg
将硬脂熔化。在40℃下将磨成粉状的活性物质均匀分散。将其冷却至38℃并倒入到微冷的栓剂模型中。
在本发明的一个特别优选的实施方案中，氟班色林以特定薄膜包衣片剂的形式给药。这些优选的制剂的实例列在下面。下列的薄膜包衣片剂可根据本领域已知的方法制备得到(参照WO 03/097058)。
G)薄膜包衣片剂
片心
| 组分 | mg/每一片剂 |
| 氟班色林 | 25.000 |
| 乳糖一水合物 | 71.720 |
| 微晶纤维素 | 23.905 |
| HPMC(Methocel E5) | 1.250 |
| 羧甲基纤维素钠 | 2.500 |
| 硬脂酸镁 | 0.625 |
包衣
| 组分 | mg/每一片剂 |
| HPMC(Methocel E5) | 1.440 |
| 聚乙二醇6000 | 0.420 |
| 二氧化钛 | 0.600 |
| 滑石 | 0.514 |
| 铁红 | 0.026 |
| 薄膜包衣片剂合计 | 128.000 |
H)薄膜包衣片剂
片心
| 组分 | mg/每一片剂 |
| 氟班色林 | 50.000 |
| 乳糖一水合物 | 143.440 |
| 微晶纤维素 | 47.810 |
| HPMC(例如Pharmacoat 606) | 2.500 |
| 羧甲基纤维素钠 | 5.000 |
| 硬脂酸镁 | 1.250 |
包衣
| 组分 | mg/每一片剂 |
| HPMC(例如Pharmacoat 606) | 2.400 |
| 聚乙二醇6000 | 0.700 |
| 二氧化钛 | 1.000 |
| 滑石 | 0.857 |
| 铁红 | 0.043 |
| 薄膜包衣片剂合计 | 255.000 |
I)薄膜包衣片剂
片心
| 组分 | mg/每一片剂 |
| 氟班色林 | 100.000 |
| 乳糖一水合物 | 171.080 |
| 微晶纤维素 | 57.020 |
| HPMC(例如Methocel E5) | 3.400 |
| 羧甲基纤维素钠 | 6.800 |
| 硬脂酸镁 | 1.700 |
包衣
| 组分 | mg/每一片剂 |
| HPMC(例如Methocel E5) | 3.360 |
| 聚乙二醇6000 | 0.980 |
| 二氧化钛 | 1.400 |
| 滑石 | 1.200 |
| 铁红 | 0.060 |
| 薄膜包衣片剂合计 | 347.000 |
J)薄膜包衣片剂
片心
| 组分 | mg/每一片剂 |
| 氟班色林 | 2.000 |
| 无水的磷酸氢钙 | 61.010 |
| 微晶纤维素 | 61.010 |
| HPMC(Methocel E5) | 1.950 |
| 羧甲基纤维素钠 | 2.600 |
| 胶态二氧化硅 | 0.650 |
| 硬脂酸镁 | 0.780 |
包衣
| 组分 | mg/每一片剂 |
| HPMC(Methocel E5) | 1.440 |
| 聚乙二醇6000 | 0.420 |
| 二氧化钛 | 0.600 |
| 滑石 | 0.514 |
| 铁红 | 0.026 |
| 薄膜包衣片剂合计 | 133.000 |
K)薄膜包衣片剂
片心
| 组分 | mg/每一片剂 |
| 氟班色林 | 100.000 |
| 无水的磷酸氢钙 | 69.750 |
| 微晶纤维素 | 69.750 |
| HPMC(例如Methocel E5) | 2.750 |
| 羧甲基纤维素钠 | 5.000 |
| 胶态二氧化硅 | 1.250 |
| 硬脂酸镁 | 1.500 |
包衣
| 组分 | mg/每一片剂 |
| HPMC(例如Methocel E5) | 2.400 |
| 聚乙二醇6000 | 0.700 |
| 二氧化钛 | 1.043 |
| 滑石 | 0.857 |
| 薄膜包衣片剂合计 | 255.000 |
L)薄膜包衣片剂
片心
| 组分 | mg/每一片剂 |
| 氟班色林 | 20.000 |
| 乳糖一水合物 | 130.000 |
| 微晶纤维素 | 43.100 |
| 羟丙基纤维素(例如Klucel LF) | 1.900 |
| 羟基乙酸淀粉钠 | 4.000 |
| 硬脂酸镁 | 1.000 |
包衣
| 组分 | mg/每一片剂 |
| HPMC(例如Methocel E5) | 2.400 |
| 聚乙二醇6000 | 0.700 |
| 二氧化钛 | 1.043 |
| 滑石 | 0.857 |
| 薄膜包衣片剂合计 | 205.000 |
Claims (9)
1.治疗经前期疾病的方法，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
2.根据权利要求1的治疗经前期疾病的方法，所述经前期疾病选自：经前期焦虑、经前期综合征和经前期焦虑症。
3.治疗女性性厌恶障碍的方法，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
4.治疗女性性唤醒障碍的方法，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
5.治疗女性性高潮障碍的方法，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
6.治疗女性性交痛障碍的方法，所述方法包括给药治疗有效量的任选为其药学上可接受的酸加成盐形式的氟班色林。
7.根据权利要求6的治疗性交痛障碍的方法，所述性交痛障碍选自：交媾困难、阴道痉挛、非接触式性交痛障碍、由一般疾病症状导致的性功能障碍及物质引起的性功能障碍。
8.根据权利要求1至7中任一项所述的方法，其特征在于氟班色林是以药学上可接受的酸加成盐的形式应用，其中该酸加成盐选自由琥珀酸、氢溴酸、醋酸、延胡索酸、马来酸、甲磺酸、乳酸、磷酸、盐酸、硫酸、酒石酸、柠檬酸及其混合物所形成的盐。
9.根据权利要求1至8中任一项所述的方法，其特征在于氟班色林是以每日0.1-400mg的剂量范围使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56466004P | 2004-04-22 | 2004-04-22 | |
| US60/564,660 | 2004-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1946403A true CN1946403A (zh) | 2007-04-11 |
Family
ID=34965482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800126174A Pending CN1946403A (zh) | 2004-04-22 | 2005-04-18 | 氟班色林在治疗经前期及其他女性的性功能障碍中的用途 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20050239798A1 (zh) |
| EP (1) | EP1740180B1 (zh) |
| JP (1) | JP2007533687A (zh) |
| KR (1) | KR20070014186A (zh) |
| CN (1) | CN1946403A (zh) |
| AR (1) | AR048833A1 (zh) |
| AT (1) | ATE474578T1 (zh) |
| AU (1) | AU2005235423A1 (zh) |
| BR (1) | BRPI0510094A (zh) |
| CA (2) | CA2563167C (zh) |
| DE (1) | DE602005022427D1 (zh) |
| ES (1) | ES2345894T3 (zh) |
| IL (1) | IL178758A0 (zh) |
| MX (1) | MXPA06012116A (zh) |
| NZ (1) | NZ551418A (zh) |
| PE (1) | PE20060257A1 (zh) |
| RU (1) | RU2384333C2 (zh) |
| TW (1) | TW200603807A (zh) |
| UY (1) | UY28860A1 (zh) |
| WO (1) | WO2005102343A1 (zh) |
| ZA (1) | ZA200608024B (zh) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| MXPA06012059A (es) * | 2004-04-22 | 2007-01-25 | Boehringer Ingelheim Int | Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii. |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| CA2599721A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| CA2608249A1 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| CA2608363A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
| JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| WO2007048803A1 (en) * | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| WO2007128802A2 (en) * | 2006-05-09 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| CA2657043A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
| US20090239881A1 (en) * | 2006-07-14 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| EA200900264A1 (ru) * | 2006-08-14 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиции флибансерина и способ их приготовления |
| EA200900270A1 (ru) * | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Системы регулируемого высвобождения и способ их приготовления |
| JP2010513390A (ja) * | 2006-12-20 | 2010-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 混合セロトニン受容体親和性を有する硫酸化ベンズイミダゾロン誘導体 |
| JP5087011B2 (ja) * | 2007-01-23 | 2012-11-28 | 馨 井上 | 眼疾患モデル用非ヒト動物 |
| EP2129400A2 (en) * | 2007-03-28 | 2009-12-09 | Boehringer Ingelheim International GmbH | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders |
| PE20091188A1 (es) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US987388A (en) * | 1910-10-13 | 1911-03-21 | William F Marsh | Fertilizer-drill attachment to cultivators and plows. |
| US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
| US3406178A (en) * | 1964-02-04 | 1968-10-15 | Monsanto Chem Australia Ltd | Preparation of 2-substituted benzimidazoles |
| US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
| US4200641A (en) * | 1976-12-21 | 1980-04-29 | Janssen Pharmaceutica, N.V. | 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| IT1176613B (it) * | 1984-08-14 | 1987-08-18 | Ravizza Spa | Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione |
| GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| HUT43600A (en) * | 1985-06-22 | 1987-11-30 | Sandoz Ag | Process for production of new thiazole derivatives and medical compound containing those |
| GB8601160D0 (en) * | 1986-01-17 | 1986-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
| US5036088A (en) * | 1986-06-09 | 1991-07-30 | Pfizer Inc. | Antiallergy and antiinflammatory agents, compositions and use |
| JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| GB8830312D0 (en) * | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| US4954503A (en) * | 1989-09-11 | 1990-09-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(1-substituted-4-piperazinyl)-1H-indazoles |
| NZ241613A (en) * | 1991-02-27 | 1993-06-25 | Janssen Pharmaceutica Nv | Highlighting intagliations in tablets |
| SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5225417A (en) * | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
| US5492907A (en) * | 1992-12-09 | 1996-02-20 | The United States Of America As Represented By The Department Of Health & Human Services | Antipsychotic composition and method of treatment |
| FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
| FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US5883094A (en) * | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
| US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
| US6083947A (en) * | 1996-01-29 | 2000-07-04 | The Regents Of The University Of California | Method for treating sexual dysfunctions |
| US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| JP2001504851A (ja) * | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用 |
| US20040023948A1 (en) * | 1997-03-24 | 2004-02-05 | Green Richard David | Fast-dispersing dosage form containing 5-HT1 agonists |
| ATE277606T1 (de) * | 1997-06-11 | 2004-10-15 | Procter & Gamble | Filmüberzogene tablette für verbesserte verträglichkeit im oberen magen-darmtrakt |
| DE69815003T2 (de) * | 1997-09-10 | 2004-04-01 | Takeda Chemical Industries, Ltd. | Stabilisierte pharmazeutische Zusammensetzung |
| JP3724157B2 (ja) * | 1997-10-30 | 2005-12-07 | コニカミノルタホールディングス株式会社 | 映像観察装置 |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| US20020151543A1 (en) * | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
| US6068846A (en) * | 1998-08-05 | 2000-05-30 | Melaleuca, Incorporated | Methods and materials for treating depression and mood disorder |
| EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| US6680071B1 (en) * | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| IT1313625B1 (it) * | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
| JP2003523382A (ja) * | 2000-02-24 | 2003-08-05 | ファルマシア・アンド・アップジョン・カンパニー | 新規な薬物の組合せ |
| US6521623B1 (en) * | 2000-09-19 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
| US6586435B2 (en) * | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| EP1256343B1 (en) * | 2001-05-11 | 2006-07-05 | Jürgen K. Dr. Beck | Flibanserin for the treatment of extrapyramidal movement disorders |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| WO2003097058A1 (en) * | 2002-05-22 | 2003-11-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pharmaceutical compositions containing flibanserin polymorph a |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| US20040132697A1 (en) * | 2002-11-06 | 2004-07-08 | Pfizer Inc. | Treatment of female sexual dysfunction |
| US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
| GB2396086C (en) * | 2002-12-03 | 2007-11-02 | Vetco Gray Controls Ltd | A system for use in controlling a hydrocarbon production well |
| WO2004063864A2 (en) * | 2003-01-06 | 2004-07-29 | Laura Berman | Method and system for computerized sexual function assessment of female users |
| US20050004105A1 (en) * | 2003-01-29 | 2005-01-06 | Emer Leahy | Treatment for a attention-deficit hyperactivity disorder |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| BRPI0411985A (pt) * | 2003-07-16 | 2006-08-29 | Pfizer | tratamento da disfunção sexual |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| MXPA06012059A (es) * | 2004-04-22 | 2007-01-25 | Boehringer Ingelheim Int | Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii. |
| US20060014757A1 (en) * | 2004-07-14 | 2006-01-19 | Boehringer Ingelheim Pharmaceuticals | Method for the treatment of anorexia nervosa |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| CA2599721A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| CA2608249A1 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| US20060258640A1 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
| CA2608363A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| JP2009503020A (ja) * | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| WO2007048803A1 (en) * | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| CA2641917A1 (en) * | 2006-02-18 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
| JP2009527525A (ja) * | 2006-02-20 | 2009-07-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁治療用のベンゾイミダゾロン誘導体 |
| US20090247546A1 (en) * | 2006-02-28 | 2009-10-01 | Boehringer Ingelheim International Gmbh | Treatment of Prevention of Valvular Heart Disease with Flibanserin |
| WO2007128802A2 (en) * | 2006-05-09 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
| JP2009541443A (ja) * | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| CA2657043A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
| US20090239881A1 (en) * | 2006-07-14 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments |
| EA200900264A1 (ru) * | 2006-08-14 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиции флибансерина и способ их приготовления |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| EA200900270A1 (ru) * | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Системы регулируемого высвобождения и способ их приготовления |
-
2005
- 2005-04-04 US US11/097,939 patent/US20050239798A1/en not_active Abandoned
- 2005-04-18 KR KR1020067024530A patent/KR20070014186A/ko not_active Application Discontinuation
- 2005-04-18 DE DE602005022427T patent/DE602005022427D1/de active Active
- 2005-04-18 NZ NZ551418A patent/NZ551418A/en unknown
- 2005-04-18 AU AU2005235423A patent/AU2005235423A1/en not_active Abandoned
- 2005-04-18 JP JP2007508812A patent/JP2007533687A/ja active Pending
- 2005-04-18 CA CA2563167A patent/CA2563167C/en not_active Expired - Fee Related
- 2005-04-18 WO PCT/EP2005/004086 patent/WO2005102343A1/en active Application Filing
- 2005-04-18 ES ES05735420T patent/ES2345894T3/es active Active
- 2005-04-18 AT AT05735420T patent/ATE474578T1/de active
- 2005-04-18 EP EP05735420A patent/EP1740180B1/en active Active
- 2005-04-18 RU RU2006140964/14A patent/RU2384333C2/ru not_active IP Right Cessation
- 2005-04-18 CN CNA2005800126174A patent/CN1946403A/zh active Pending
- 2005-04-18 MX MXPA06012116A patent/MXPA06012116A/es active IP Right Grant
- 2005-04-18 CA CA2802600A patent/CA2802600A1/en not_active Abandoned
- 2005-04-18 BR BRPI0510094-1A patent/BRPI0510094A/pt not_active IP Right Cessation
- 2005-04-19 UY UY28860A patent/UY28860A1/es not_active Application Discontinuation
- 2005-04-20 PE PE2005000433A patent/PE20060257A1/es not_active Application Discontinuation
- 2005-04-21 TW TW094112654A patent/TW200603807A/zh unknown
- 2005-04-22 AR ARP050101599A patent/AR048833A1/es not_active Suspension/Interruption
-
2006
- 2006-09-27 ZA ZA200608024A patent/ZA200608024B/xx unknown
- 2006-10-19 IL IL178758A patent/IL178758A0/en unknown
-
2012
- 2012-07-27 US US13/559,852 patent/US20130079356A1/en not_active Abandoned
-
2014
- 2014-09-03 US US14/475,755 patent/US20150111898A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200608024B (en) | 2007-12-27 |
| US20150111898A1 (en) | 2015-04-23 |
| AU2005235423A1 (en) | 2005-11-03 |
| JP2007533687A (ja) | 2007-11-22 |
| UY28860A1 (es) | 2005-11-30 |
| RU2006140964A (ru) | 2008-05-27 |
| CA2563167C (en) | 2013-04-02 |
| KR20070014186A (ko) | 2007-01-31 |
| ATE474578T1 (de) | 2010-08-15 |
| BRPI0510094A (pt) | 2007-10-16 |
| AR048833A1 (es) | 2006-05-31 |
| RU2384333C2 (ru) | 2010-03-20 |
| US20130079356A1 (en) | 2013-03-28 |
| PE20060257A1 (es) | 2006-04-11 |
| IL178758A0 (en) | 2007-03-08 |
| TW200603807A (en) | 2006-02-01 |
| CA2563167A1 (en) | 2005-11-03 |
| WO2005102343A1 (en) | 2005-11-03 |
| DE602005022427D1 (de) | 2010-09-02 |
| US20050239798A1 (en) | 2005-10-27 |
| EP1740180A1 (en) | 2007-01-10 |
| MXPA06012116A (es) | 2007-01-17 |
| ES2345894T3 (es) | 2010-10-05 |
| NZ551418A (en) | 2009-09-25 |
| EP1740180B1 (en) | 2010-07-21 |
| CA2802600A1 (en) | 2005-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1946403A (zh) | 氟班色林在治疗经前期及其他女性的性功能障碍中的用途 | |
| KR101235102B1 (ko) | 플리반세린을 포함하는 성욕 장애 치료용 약제학적 조성물 | |
| CN1213754C (zh) | β－咔啉药物组合物 | |
| EP1888070A1 (en) | Method for the treatment of sexual dysfunctions due to medical conditions | |
| JP4773456B2 (ja) | 生体利用率を向上させた経口用製剤 | |
| CN1787811A (zh) | 口腔崩解片 | |
| CN1350454A (zh) | 阿朴吗啡和西地拉非组合物 | |
| EP1789048A1 (en) | Method for the treatment of attention deficit hyperactivity disorder | |
| JP2008506688A (ja) | 神経性無食欲症の治療方法 | |
| CN1458844A (zh) | 二酮基哌嗪和包含它们的组合物的使用方法 | |
| CN101073563A (zh) | 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片 | |
| CN1863517A (zh) | 快速崩解制剂 | |
| CN1216034C (zh) | 特比萘芬的苹果酸加成盐 | |
| CN1197556C (zh) | 一种防治放疗、化疗呕吐的口腔快速崩解片剂及制备方法 | |
| CN1309379C (zh) | 细辛脑滴丸及其制备方法 | |
| CN1245980C (zh) | 一种治疗抑郁症的口服缓、控释制剂 | |
| CN1618428A (zh) | 头孢羟氨苄口腔崩解片及其制备方法 | |
| CN1695617A (zh) | 甲磺酸氨氯地平口腔崩解片及其制备方法 | |
| CN1820739A (zh) | 盐酸西布曲明咀嚼片及其制备方法 | |
| CN1526379A (zh) | 盐酸西布曲明滴丸及其制备方法 | |
| CN1915233A (zh) | 一种治疗焦虑症的药物组合物及其口崩制剂 | |
| CN1839820A (zh) | 含西酞普兰和环糊精的抗抑郁口服药用组合物 | |
| CN1679541A (zh) | 茶色素滴丸及其制备方法 | |
| CN1562067A (zh) | 阿奇霉素口腔崩解片及其制备方法 | |
| CN1723882A (zh) | 舌下、颊或鼻腔给药的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20070411 |